<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Logviniuk D</submitter><funding>Israel Science Foundation</funding><funding>Ministerio de Ciencia e Innovaci?n</funding><funding>?la Caixa? Foundation</funding><pagination>5965-5975</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8991007</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>144(13)</volume><pubmed_abstract>Each year, infections caused by fungal pathogens claim the lives of about 1.6 million people and affect the health of over a billion people worldwide. Among the most recently developed antifungal drugs are the echinocandins, which noncompetitively inhibit β-glucan synthase, a membrane-bound protein complex that catalyzes the formation of the main polysaccharide component of the fungal cell wall. Resistance to echinocandins is conferred by mutations in &lt;i>FKS&lt;/i> genes, which encode the catalytic subunit of the β-glucan synthase complex. Here, we report that selective removal of the benzylic alcohol of the nonproteinogenic amino acid 3&lt;i>S&lt;/i>,4&lt;i>S&lt;/i>-dihydroxy-l-homotyrosine of the echinocandins anidulafungin and rezafungin, restored their efficacy against a large panel of echinocandin-r</pubmed_abstract><journal>Journal of the American Chemical Society</journal><pubmed_title>Benzylic Dehydroxylation of Echinocandin Antifungal Drugs Restores Efficacy against Resistance Conferred by Mutated Glucan Synthase.</pubmed_title><pmcid>PMC8991007</pmcid><funding_grant_id>PGC2018-099921-B-I00</funding_grant_id><funding_grant_id>LCF/PR/HR21/00737</funding_grant_id><funding_grant_id>LCF/PR/GN18/50310010</funding_grant_id><funding_grant_id>179/19</funding_grant_id><pubmed_authors>Jaber QZ</pubmed_authors><pubmed_authors>Kozer N</pubmed_authors><pubmed_authors>Dobrovetsky R</pubmed_authors><pubmed_authors>Ksiezopolska E</pubmed_authors><pubmed_authors>Gabaldon T</pubmed_authors><pubmed_authors>Fridman M</pubmed_authors><pubmed_authors>Logviniuk D</pubmed_authors><pubmed_authors>Carmeli S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Benzylic Dehydroxylation of Echinocandin Antifungal Drugs Restores Efficacy against Resistance Conferred by Mutated Glucan Synthase.</name><description>Each year, infections caused by fungal pathogens claim the lives of about 1.6 million people and affect the health of over a billion people worldwide. Among the most recently developed antifungal drugs are the echinocandins, which noncompetitively inhibit β-glucan synthase, a membrane-bound protein complex that catalyzes the formation of the main polysaccharide component of the fungal cell wall. Resistance to echinocandins is conferred by mutations in &lt;i>FKS&lt;/i> genes, which encode the catalytic subunit of the β-glucan synthase complex. Here, we report that selective removal of the benzylic alcohol of the nonproteinogenic amino acid 3&lt;i>S&lt;/i>,4&lt;i>S&lt;/i>-dihydroxy-l-homotyrosine of the echinocandins anidulafungin and rezafungin, restored their efficacy against a large panel of echinocandin-r</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-04-05T13:24:10.898Z</modification><creation>2025-04-05T13:24:10.898Z</creation></dates><accession>S-EPMC8991007</accession><cross_references><pubmed>35347986</pubmed><doi>10.1021/jacs.2c00269</doi></cross_references></HashMap>